Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2013 Oct;69(4):513.e1-8; quiz 521-2. doi: 10.1016/j.jaad.2013.06.040.

Kawasaki disease: part II. Complications and treatment.

Author information

  • 1Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Abstract

Kawasaki disease, or mucocutaneous lymph node syndrome, is the leading cause of acquired heart disease in children in the United States and other developed countries. Coronary artery lesions are the most significant cause of morbidity and mortality. Treatment should ideally be provided within 10 days of symptom onset to reduce the risk of coronary artery complications. The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients. Some patients do not respond to intravenous immunoglobulin and require additional therapy. Part II of this continuing medical education article will focus on the complications of Kawasaki disease and potential treatment options.

Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

KEYWORDS:

C-reactive protein; CRP; IVIG; KD; Kawasaki disease; aspirin; complications; coronary artery lesions; corticosteroids; intravenous immunoglobulin; mucocutaneous lymph node syndrome; pediatric; treatment; vasculitis

PMID:
24034380
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk